Literature DB >> 24568737

Inhibition of TNF receptor signaling by anti-TNFα biologicals primes naïve CD4(+) T cells towards IL-10(+) T cells with a regulatory phenotype and function.

Martine A Boks1, Judith R Kager-Groenland1, Charlotte M Mousset1, S Marieke van Ham1, Anja ten Brinke2.   

Abstract

TNFα is a potent pro-inflammatory cytokine playing a pivotal role in several autoimmune diseases. Little is known about the mechanism of TNFα blocking agents on naïve T cell differentiation. Here, we report that neutralizing TNFα during priming of naïve CD4(+) T cells by dendritic cells favors development of IL-10(+) T helper cells. TNFα counteracts IL-10(+) T cell priming mainly via TNFRI receptor signaling. While initial T cell activation was not affected, neutralization of TNFα negatively affected sustained T cell differentiation in later stages of T cell priming. Whole genome gene expression analysis revealed an extended regulatory gene profile for anti-TNFα-treated T cells. Indeed, neutralizing TNFα during naïve T cell priming enhanced the suppressive function of anti-TNFα-treated T cells. Taken together, inhibition of TNFα-TNFR interaction shifts the balance of Th cell differentiation towards IL-10 expressing suppressive T cells, which may be one of the beneficial mechanisms in TNFα blocking therapies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-TNFα therapy; IL-10; Regulatory T cells; T cell polarization; TNF receptor

Mesh:

Substances:

Year:  2014        PMID: 24568737     DOI: 10.1016/j.clim.2014.02.008

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

1.  Collagen I-induced dendritic cells activation is regulated by TNF-alpha production through down-regulation of IRF4.

Authors:  Barun Poudel; Hyeon-Hui Ki; Young-Mi Lee; Dae-Ki Kim
Journal:  J Biosci       Date:  2015-03       Impact factor: 1.826

2.  TNF Blockade Maintains an IL-10+ Phenotype in Human Effector CD4+ and CD8+ T Cells.

Authors:  Ceri A Roberts; Lucy E Durham; Veerle Fleskens; Hayley G Evans; Leonie S Taams
Journal:  Front Immunol       Date:  2017-02-15       Impact factor: 7.561

Review 3.  Tumour necrosis factor signalling in health and disease.

Authors:  Jonathan Holbrook; Samuel Lara-Reyna; Heledd Jarosz-Griffiths; Michael McDermott
Journal:  F1000Res       Date:  2019-01-28

4.  IKZF3/Aiolos Is Associated with but Not Sufficient for the Expression of IL-10 by CD4+ T Cells.

Authors:  Michael L Ridley; Veerle Fleskens; Ceri A Roberts; Sylvine Lalnunhlimi; Aldana Alnesf; Aoife M O'Byrne; Kathryn J A Steel; Giovanni A M Povoleri; Jonathan Sumner; Paul Lavender; Leonie S Taams
Journal:  J Immunol       Date:  2020-04-22       Impact factor: 5.422

5.  A Praziquantel Treatment Study of Immune and Transcriptome Profiles in Schistosoma haematobium-Infected Gabonese Schoolchildren.

Authors:  Lucja A Labuda; Ayola A Adegnika; Bruce A Rosa; John Martin; Ulysse Ateba-Ngoa; Abena Serwaa Amoah; Honorine Mbenkep Lima; Lynn Meurs; Moustapha Mbow; Mikhael D Manurung; Jeannot F Zinsou; Hermelijn H Smits; Peter G Kremsner; Makedonka Mitreva; Maria Yazdanbakhsh
Journal:  J Infect Dis       Date:  2020-11-13       Impact factor: 5.226

6.  TNFA -308G>A and IL10 -1082A>G polymorphisms seem to be predictive biomarkers of chronic HCV infection.

Authors:  Angélica Menezes Santiago; Ednelza da Silva Graça Amoras; Maria Alice Freitas Queiroz; Simone Regina Souza da Silva Conde; Izaura Maria Vieira Cayres-Vallinoto; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  BMC Infect Dis       Date:  2021-11-03       Impact factor: 3.090

Review 7.  The Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid Arthritis.

Authors:  Ceri A Roberts; Abigail K Dickinson; Leonie S Taams
Journal:  Front Immunol       Date:  2015-11-19       Impact factor: 7.561

8.  Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.

Authors:  A Vultaggio; G Petroni; S Pratesi; F Nencini; D Cammelli; M Milla; F Prignano; V Annese; S Romagnani; E Maggi; A Matucci
Journal:  Clin Exp Immunol       Date:  2016-10-26       Impact factor: 4.330

9.  T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis.

Authors:  Sara Pratesi; Francesca Nencini; Francesca Grosso; Laura Dies; Susanna Bormioli; Daniele Cammelli; Enrico Maggi; Andrea Matucci; Alessandra Vultaggio
Journal:  Front Immunol       Date:  2019-01-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.